All News
ACR 2025 – Day 2 Report
Here are 3 abstracts that caught my eye on Day 2 at ACR25. Notably these have takeaway messages that should support your current practices.
Read Article
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Is AI Smarter than a Doctor?
Dr. Janet Pope reviews key takeaways from the session, "Artificial Intelligence in Medical Education: From Theory to Practice," at #ACR25.
https://t.co/F6KEYAWi75 https://t.co/m57asdLGrn
Dr. John Cush RheumNow ( View Tweet)
@RheumNow Plus a heap more biosimilars have broken through in the US in the last year. It feels the biosimilar era is now here stateside, too.
#ACR25 FDA Update @RheumNow https://t.co/9RiyhbKXU4
David Liew drdavidliew ( View Tweet)
@US_FDA rheumatology approvals, 2025
#ACR25 @RheumNow https://t.co/uVLWqBx45m
David Liew drdavidliew ( View Tweet)
Can a Fitbit track RA?
This Japanese clinic is using Fitbit data and have seen it correlate with CDAI across their RA clinic.
Maybe instead of asking about our patients mobility and sleep, we should be measuring it?
#ACR25 ABST2253 @RheumNow https://t.co/rg2SKgn7K2
David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Adding social risk factors to the mix
Abstract 1917: WashU Rheumatology examined SRF screening in the clinic
🔹 50% screened once; 1/3 screened > 1
🔹 Core SRFs (finance, transport, housing, food) relatively stable
🔹 Biggest change over time: stress
@RheumNow #ACR25 https://t.co/oKlwMZ77nB
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Can AI predict who stops their RA meds?
In older adults on b/tsDMARDs, interpretable ML found frailty, comorbidity & age top the list for nonadherence risk.
@RheumNow #ACR25 Abstract#2287
Jiha Lee JihaRheum ( View Tweet)
Paging the pharmacist
Abstract 1973: Dedicated clinic pharmacist -> benefits
Tasks included:
🔹 74% PA support
🔹 55% patient education
🔹 40% medication management
~50% pts had clinically meaningful improvement
Providers report ↑ care quality & ↓ admin burden
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Excited (and a little nervous!) to be presenting on a topic I’m very passionate about- social determinants of health & shared decision making, alongside some fantastic speakers & chairs.
Join us in room W184D, 10:00-11:30
Looking forward to a lively discussion!
#ACR25 @RheumNow https://t.co/FsDDrjisR3
Mrinalini Dey DrMiniDey ( View Tweet)
#ClinicalPearl
#seroneg #arthritis often has
👇
#involvement of
1st toe IP joint
Look at the feet 🦶
@RheumNow @ACRheum #ACR25
#28T08
Session secrets &pearls Tues https://t.co/EfqkLsTKmt
Janet Pope Janetbirdope ( View Tweet)
Overview of the use of SARD-ILD by @drdavidliew covering the challenges, professionalism, explainability and interpretability. Think of using and validating AI in the same way we train our residents. The human interface still needed @RheumNow #ACR25 https://t.co/TYKud057ag
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
🎥 LIVE from #ACR25
Join us daily at 5 PM CST for RheumNow’s ACR Recap Live -
Your must-watch debrief of the day’s biggest breakthroughs, hot abstracts, and real-time clinical takeaways.
Streaming on YouTube Live, Facebook Live, X-Live & LinkedIn Live.
Save the time. Be part of https://t.co/ZgZM14L6ta
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
#ACR25 Day 1 RECAP
Big takeaways, standout moments, and what set the tone for this year’s conference. We break down the key insights, early trends, and conversations shaping Day 1.
https://t.co/js5FVBvUfk https://t.co/smh1AyPhfa
Dr. John Cush RheumNow ( View Tweet)
Delay in PsA diagnosis
Meta Analysis of 32000+ pts
Median diagnostic delay 2.5 years
Median delay in referral 1 year
Increase odds of Rx damage from 50%
Geographic variation
We need to do better
#ACR25 @RheumNow #ABSTRACT1713 https://t.co/CWwqosa5NT
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
PMR patients need healthcare professionals who know a bit about their disease.
Survey of US HCPs, amongst responders:
- 68% were not aware/unsure about PMR
- of those who were aware, knowledge was… not great (see below)
PMR needs everyone’s respect
#ACR25 ABST1617 @RheumNow https://t.co/SpyEnAW8lI
David Liew drdavidliew ( View Tweet)
In a Brazilian cohort (n=791), axSpA diagnosis delay dropped from 41.7 yrs (1960s) to 1.9 yrs (2020s). Female representation rose to 50%. Non-radiographic axSpA now 16.7%. MRI and updated criteria driving earlier, more equitable recognition. Abstract#1407 @RheumNow #ACR25 https://t.co/8hIpX0a1Sa
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
